Single-dose pharmacokinetics of rifapentine in women

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 26, Issue 1, 1998, Pages 75-85

  Keung, Anther C F ^a   Eller, Mark G ^a   Weir, Scott J ^a  

^a SANOFI   (France)

Author keywords

Female; Gender differences; Pharmacokinetics; Rifapentine

Indexed keywords

DRUG METABOLITE; RIFAPENTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEACETYLATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENDER; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SIDE EFFECT; URINE COLOR;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; DEALKYLATION; FEMALE; HALF-LIFE; HUMANS; MIDDLE AGED; RIFAMPIN;

EID: 0031684908     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. W. Wehrli. Rifampin: mechanisms of action and resistance. Rev. Infect. Dis. 5(Suppl. 3)S407-S411 (1983).
2. J. M. Dickinson and D. A. Mitchison. In vitro activity of selected rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 68:177-182 (1987).
3. L. B. Heifets, P. J. Lindholm-Levy, and M. A. Flory. Bactericidal activity in vitro of various rifamycins against M. avium and M. tuberculosis. Am. Rev. Resp. Dis. 141:626-630 (1990).
4. N. Mor, B. Simon, N. Mezo, and L. Heifets. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39:2073-2077 (1995).
5. 14C-rifapentine in healthy volunteers. Drug Metab. Dispos. (submitted for publication).
6. A. T. Birmingham, A. J. Coleman, M. L'E. Orme, B. K. Park, N. J. Pearson, A. H. Short, and P. J. Southgate. Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin). Br. J. Clin. Pharmacol. 6:455P-456P (1978).
7. G. Buniva, D. Sassella, and G. M. Frigo. Pharmacokinetics of rifapentine in man. Proc. Int. Congr. Chemother. 111:29-33 (1983).
8. A. C. F. Keung, T. D. Miller, V. I. Green, M. Ames, M. G. Eller, and S. J. Weir. Bioavailability (BA) and food effect study of rifapentine in healthy adults [abstract]. Pharm. Res. 12(Suppl.): S419 (1995).
9. Y. Biya, N. Xikuam, Z. Lizhen, and Z. Fengying. Absorption and elimination of cyclopentyl-rifamycin in human subjects. Chinese J. Tuberc. Resp. Dis. 10:267-268 (1987).
10. S. L. Chan, W. W. Yew, J. H. D. Porter, K. P. W. J. McAdam, B. W. Allen, and J. M. Dickinson. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int. J. Antimicrob. Agents 3:267-274 (1994).
11. Z. Qing, C. Yijan, and Z. Yingyuan. Clinical pharmacokinetic study on rifapentine. Chinese J. Antibiot. 19:456-458 (1994).
12. C. Zheng, L. Yi, and Z. Huiyan. Pharmacokinetics of domestic rifapentine in patients with acute pulmonary infections. Chinese J. Antibiot. 12:333-336 (1987).
13. A. Keung, M. G. Eller, K. A. McKenzie, and S. J. Weir. Single and multiple dose pharmacokinetics of rifapentine and its active metabolite 25-desacetyl-rifapentine in man. Pharmacol. Ther. (submitted for publication).
14. J. C. Bennet. Inclusion of women in clinical trials: Policies for population subgroups. Int. J. Tuber. Lung Dis. 329:288-292 (1993).
15. R. B. Merkatz, R. Temple, S. Sobel, K. Feiden, and D. A. Kessler. Women in clinical trials of new drugs. A change in Food and Drug Administration policy. New Engl. J. Med. 329:292-296 (1993).
16. C. V. Fletcher, E. P. Acosta, and J. M. Strykowski. Gender differences in human pharmacokinetics and pharmacodynamics. J. Adolescent Health 15:619-629 (1994).
17. C. H. Gleiter and U. Gundert-Remy. Gender differences in pharmacokinetics. Eur. J. Drug Metab. Pharmacokin. 21:123-128 (1996).
18. R. Z. Harris, L. Z. Benet, and J. B. Schwartz. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50:222-239 (1995).
19. K. A. Yonkers, J. C. Kando, J. O. Cole, and S. Blumenthal. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiat. 149:587-595 (1992).
20. J. C. Kando, K. A. Yonkers, and J. O. Cole. Gender as a risk factor for adverse events to medications. Drugs 50:1-6 (1995).
21. American College of Clinical Pharmacy. ACCP White paper: Women as research subjects. Pharmacotherapy 13:534-542 (1993).
22. R. Scotti. Sex differences in blood levels of some antibiotics. Chemotherapy 18:205-211 (1973).
23. H. Iwainsky, K. Winsel, E. Werner, and H. Eule. On the pharmacokinetics of rifampicin during treatment with intermittent administration. II. Influence of age and sex of the patients. Scand. J. Resp. Dis. 57:5-11 (1976).
24. L. Verbist. Rifampicin blood levels in man. Acta Tuberc. Pneumol. Belg. 60:288-298 (1969).
25. M. D. Holland. Rifampicin - what dose for pulmonary tuberculosis? South Afr. Med. J. 46:604-608 (1972).
26. D. C. Colborn, R. C. Li, and P. K. Narang. Influence of gender on rifabutin (R) kinetics [abstr.]. Clin. Pharmacol. Ther. 53:182 (1993).
27. F-J. Leinweber. Possible physiological roles of carboxylic ester hydrolases. Drug Metab. Rev. 18:379-439 (1987).
28. L. Verbist. Pharmacological study of rifampicin after repeated high dosage during intermittent combined therapy. I. Variation of the rifampicin serum levels. Respiration 28(Suppl. 7):7-16 (1971).
29. T. F. Blaschke and M. H. Skinner. The clinical pharmacokinetics of rifabutin. Clin. Infect. Dis. 22(Suppl. 1):S15-S22 (1996).
30. G. Cocchiara, M. Strolin Benedetti, G. P. Vicario, M. Ballabio, B. Gioia, S. Viogglio, and A. Vigevani. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 19:769-780 (1989).
31. E. Iatsimirskaia, S. Tulebaev, E. Storozhuk, I. Utkin, D. Smith, N. Gerber, and T. Koudriakova. Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin. Pharmacol. Ther. 61:554-562 (1997).
32. C. B. Trapnell, C. Jamis-Dow, R. W. Klecker, and J. M. Collins. Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: Relevance to clinical interaction with fluconazole. Antimicrob. Agents Chemother. 41:924-926 (1997).
33. 14C-rifabutin in animals and man. J. Antimicrob. Chemother. 26:813-822 (1990).